Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
2.170
-0.010 (-0.46%)
Jun 16, 2026, 1:51 PM CET
Market Cap26.69M -20.9%
Revenue (ttm)n/a
Net Income-10.73M
EPS-1.57
Shares Out 12.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume173,060
Open2.190
Previous Close2.180
Day's Range1.972 - 2.250
52-Week Range1.353 - 9.200
Beta0.25
AnalystsStrong Buy
Price Target96.90 (+4,365.44%)
Earnings DateSep 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wrocław, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 4
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements